{"id":6372,"name":"Atlantis Ventures","slug":"atlantis-ventures","website":"https://www.atlantis-ventures.com/","hqGeo":null,"stageFocus":[],"sectorTags":[],"excludedSectors":[],"checkSizeMin":null,"checkSizeMax":null,"thesisSummary":null,"thesisNarrative":null,"logoUrl":null,"aumUsd":null,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"LillianCare","companyUrl":null,"stage":"Seed/Series A","sector":"healthcare","investmentYear":null,"description":"Healthcare company focused on care delivery","amountUsd":null,"relevanceNote":null,"fundName":"Atlantis Ventures"},{"companyName":"AAVantgarde Bio","companyUrl":null,"stage":"Seed/early stage","sector":"biotech / gene therapy","investmentYear":null,"description":"Develops next-generation gene therapies for large-gene delivery","amountUsd":null,"relevanceNote":null,"fundName":"Atlantis Ventures"},{"companyName":"Accent Therapeutics","companyUrl":null,"stage":"early stage","sector":"biotech / oncology","investmentYear":null,"description":"Develops therapies targeting RNA-modifying proteins for precision cancer treatment","amountUsd":null,"relevanceNote":null,"fundName":"Atlantis Ventures"},{"companyName":"Affinia Therapeutics","companyUrl":null,"stage":"early stage","sector":"biotech / gene therapy","investmentYear":null,"description":"Gene therapy company","amountUsd":null,"relevanceNote":null,"fundName":"Atlantis Ventures"},{"companyName":"Aiolos Bio","companyUrl":null,"stage":"early stage","sector":"biotech / therapeutics","investmentYear":null,"description":"Develops treatments for respiratory and inflammatory diseases","amountUsd":null,"relevanceNote":null,"fundName":"Atlantis Ventures"},{"companyName":"Akero Therapeutics","companyUrl":null,"stage":"early stage","sector":"biotech / metabolic disease","investmentYear":null,"description":"Metabolic disease biotech focused on NASH and related conditions","amountUsd":null,"relevanceNote":null,"fundName":"Atlantis Ventures"}],"partnerCount":1,"partners":[{"id":22136,"name":"Finn Wentzler","title":"General Partner","seniority":null,"focusTags":["early-stage startups","deep tech","software"],"linkedinUrl":"https://www.linkedin.com/in/finnwentzler/de","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":null,"investmentsThisYear":0},"activityItems":[],"contentUpdatedAt":"2026-11-14T13:36:23.798Z","investorType":"vc","preferredApproach":null,"prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[],"featuredIn":[],"fundraisingResources":[{"slug":"investormatch-mcp-server-claude-chatgpt","title":"Your Investor List Now Lives Inside Claude and ChatGPT"},{"slug":"how-to-find-investors","title":"How to Find Investors: A VC's Playbook for Founders"},{"slug":"how-vcs-help-portfolio-raise-follow-on","title":"How VCs Can Actually Help Their Portfolio Companies Raise Follow-On"}],"overviewNarrative":"Atlantis Ventures is a venture capital firm that invests in early-stage startups. The firm focuses on deep tech and software through its General Partner Finn Wentzler.\n\nAtlantis Ventures maintains a portfolio of companies primarily in the biotech and healthcare sectors. The firm has recorded investments in six companies, all at the seed or early stage.","portfolioNarrative":"Atlantis Ventures has recorded investments in six portfolio companies. These include AAVantgarde Bio in biotech and gene therapy, Accent Therapeutics in biotech and oncology, Affinia Therapeutics in biotech and gene therapy, Aiolos Bio in biotech and therapeutics, Akero Therapeutics in biotech and metabolic disease, and LillianCare in healthcare. All investments were made at the Seed, early, or Series A stage.\n\nThe firm's recorded investments reflect a focus on early-stage companies developing solutions in biotechnology, gene therapy, oncology, metabolic disease, and broader healthcare.","seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-07-28T16:02:45.060Z"}